A phase II trial of afatinib (BIBW 2992) in patients (pts) with advanced non-small cell lung cancer previously treated with erlotinib (E) or gefitinib (G).
N. Yamamoto
No relevant relationships to disclose
N. Katakami
No relevant relationships to disclose
S. Atagi
No relevant relationships to disclose
T. Hida
No relevant relationships to disclose
K. Goto
Honoraria - Chugai Pharma
T. Horai
No relevant relationships to disclose
A. Inoue
No relevant relationships to disclose
Y. Ichinose
No relevant relationships to disclose
K. Kobayashi
No relevant relationships to disclose
K. Takeda
No relevant relationships to disclose
K. Kiura
Honoraria - Chugai Pharma
Research Funding - Meiji Seika Kaisha
H. Saka
No relevant relationships to disclose
T. Tamura
No relevant relationships to disclose
I. Okamoto
Honoraria - Chugai Pharma; Lilly; Taiho Pharmaceutical
N. Nogami
No relevant relationships to disclose
R. Morinaga
No relevant relationships to disclose
K. Nishio
No relevant relationships to disclose
Y. Seki
Employment or Leadership Position - Boehringer Ingelheim
R. M. Lorence
Employment or Leadership Position - Boehringer Ingelheim
M. Shahidi
Employment or Leadership Position - Boehringer Ingelheim